IMU

0.00%

5.8¢ imugene limited

Why IMU is a multi multi bagger, page-22060

First 22060 Last

Share
Profile

Follow
beardpapa

38 Posts.

25

26/03/24

10:05

Post #: 73057346
Share

Originally posted by Watmighthavben: ↑

Thanks for posting.

Just viewing from an analytical perspective it's a pity Imugene spends so much time with innuendo and at times smoke and mirrors when they are discussing what they are actually doing and what they have planned. We are now close to six months further into a trial which they have said they are prioritising, in which patients are receiving 42 day scans, and sitting around debating what may or may not be occurring. Irrespective of the so called FDA guidelines and parameters in addition to disclosure requirements during clinical trials, of which I am well aware, it's pretty poor form from Team Imugene to not keep their owners better abreast of ongoing developments in what is such a crucial component when it comes to their investment. In addition to the omission of their fast track designation approval in presentations and their failure to outline which indications the trial is currently pursuing, there has been too much grey rather than black and white when it comes to communication surrounding the trial.

If as suggested the medicine is as good as anticipated by the Team at Imugene surely there is a need to move as fast as they can to administer as many participants as possible across as many indications as the regulators shall allow. We do know how much of a key component CF33 Vaxinia is to their overall plans, when one takes into account it is a key ingredient in their Oncarlytics formula, not to mention a future addition to an Azer Cel mix. I note Dr Bradley Glover last week insinuated data would drive direction in the trial. With this in mind I would enjoy the opportunity to vote for expanding the trial even further at whatever cost with whomever the Board gets on board if these results continue to exhibit outstanding efficacy. The world is at the mercy of this insidious disease and the sooner companies such as Imugene go all out to rapidly expand clinical trials to a point where not only OBDR's are established but significant data is delivered in their "proof of concept", the better. I would ideally like to see hundreds of patients participating in this trial, in multiple cancer indications across several continents. After 18 months or whatever its been we have only 40 patients dosed. Its really quite sad, when one takes into consideration the huge unmet need present.

It's not my position to blame Imugene as they are proceeding as quickly as possible with the brief they have been afforded by the FDA to this point. But moving forward we need to consider exerting pressure on management either through a large IPO on the Nasdaq, out licensing arrangements, sale of other assets or whatever it takes to really push CF33 Vaxinia as far as it can go without monetary restrictions. The drug simply needs to be administered to as many patients as is physically possible irrespective of cost, if what we have visualised last November continues this April. Imugene cannot afford to move as slowly as they have with Her Vaxx and PD1 Vaxx, with a handful of patients and limited data delivery. The kitchen sink needs to be thrown at this one.

WMHB

Expand

"In addition to the omission of their fast track designation approval in presentations and their failure to outline which indications the trial is currently pursuing..."

Or did you just sneak that in there to get me posting again?

IMU Price at posting: 10.5¢ Sentiment: Hold Disclosure: Held
6 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 2,713 more messages in this thread...

First 22060 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.8¢		Change 0.000(0.00%)		Mkt cap ! $424.5M

Open	High	Low	Value	Volume
5.8¢	5.8¢	5.6¢	$1.032M	18.08M

Buyers (Bids)

No.	Vol.	Price($)
1	90000	5.7¢

Sellers (Offers)

Price($)	Vol.	No.
5.8¢	744737	5

View Market Depth

No.	Vol.	Price($)
1	90000	0.057
10	1292446	0.056
31	2801064	0.055
7	854500	0.054
12	693196	0.053

Price($)	Vol.	No.
0.058	299151	3
0.059	528777	3
0.060	392948	5
0.061	176830	3
0.062	152014	3

Last trade - 16.10pm 14/06/2024 (20 minute delay)


Last 5.8¢		Change 0.000 ( 1.03 %)
Open	High	Low	Volume
5.8¢	5.8¢	5.6¢	4924782
Last updated 15.59pm 14/06/2024 ?

IMU (ASX) Chart

Why IMU is a multi multi bagger, page-22060

Featured News

Whitebark launches $1.5M capital raise to progress QLD geothermal assets

Dominos looks tasty and tempting, but could be too spicy and even dicey

Maiden production at Alta Mesa puts Boss on the charge for 3Mlbs target

Lightning spots additional pegmatites during first Brazilian visit

Triangle gets approval for Perth Basin carbon sequestration project

ASX Market Close: Unemployment dips as index climbs | 13 June, 2024

Telix dips as pharma giant abandons US IPO for NASDAQ listing – despite record run

Week 24 Wrap: US contagion sentiment not so contagious; iron ore remains pressured

ASX Market Close: Consumer Discretionary rises ahead of interest rates decision | June 14, 2024

Pearl Gull Iron snaffles REE project in Chile, noting geological echoes of China

Buyers (Bids)

Sellers (Offers)

Featured News

Why IMU is a multi multi bagger, page-22060

Featured News

Top Stories

Whitebark launches $1.5M capital raise to progress QLD geothermal assets

Dominos looks tasty and tempting, but could be too spicy and even dicey

Maiden production at Alta Mesa puts Boss on the charge for 3Mlbs target

Lightning spots additional pegmatites during first Brazilian visit

Triangle gets approval for Perth Basin carbon sequestration project

ASX Market Close: Unemployment dips as index climbs | 13 June, 2024

Telix dips as pharma giant abandons US IPO for NASDAQ listing – despite record run

Week 24 Wrap: US contagion sentiment not so contagious; iron ore remains pressured

ASX Market Close: Consumer Discretionary rises ahead of interest rates decision | June 14, 2024

Pearl Gull Iron snaffles REE project in Chile, noting geological echoes of China

Buyers (Bids)

Sellers (Offers)

Featured News